- Home
- SBGI vs MESO Comparison
SBGI vs MESO Comparison
Compare SBGI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBGI
- MESO
- Stock Information
- Founded
- SBGI 1986
- MESO 2004
- Country
- SBGI United States
- MESO Australia
- Employees
- SBGI N/A
- MESO N/A
- Industry
- SBGI Broadcasting
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBGI Industrials
- MESO Health Care
- Exchange
- SBGI Nasdaq
- MESO Nasdaq
- Market Cap
- SBGI 1.1B
- MESO 1.3B
- IPO Year
- SBGI 1995
- MESO N/A
- Fundamental
- Price
- SBGI $14.46
- MESO $15.26
- Analyst Decision
- SBGI Buy
- MESO Buy
- Analyst Count
- SBGI 5
- MESO 4
- Target Price
- SBGI $18.50
- MESO $18.00
- AVG Volume (30 Days)
- SBGI 365.9K
- MESO 315.0K
- Earning Date
- SBGI 08-06-2025
- MESO 08-28-2025
- Dividend Yield
- SBGI 7.05%
- MESO N/A
- EPS Growth
- SBGI N/A
- MESO N/A
- EPS
- SBGI 1.97
- MESO N/A
- Revenue
- SBGI $3,526,000,000.00
- MESO $5,670,000.00
- Revenue This Year
- SBGI N/A
- MESO $177.23
- Revenue Next Year
- SBGI $9.59
- MESO $314.04
- P/E Ratio
- SBGI $7.21
- MESO N/A
- Revenue Growth
- SBGI 11.62
- MESO N/A
- 52 Week Low
- SBGI $12.07
- MESO $5.78
- 52 Week High
- SBGI $18.46
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- SBGI 48.46
- MESO 61.70
- Support Level
- SBGI $14.66
- MESO $14.45
- Resistance Level
- SBGI $15.69
- MESO $16.23
- Average True Range (ATR)
- SBGI 0.55
- MESO 0.56
- MACD
- SBGI -0.11
- MESO 0.20
- Stochastic Oscillator
- SBGI 25.90
- MESO 64.47
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.